牋牋Adherex Technologies Inc. (TSX: AHX) is a biopharmaceutical company with a cancer focus, a pioneering tumor vascular targeting platform and four products in clinical development.

牋牋The cancer therapeutics market is characterized by its large size, its significant growth and the need for more effective therapies to target the unmet medical needs of patients.

牋牋Adherex is a leader in tumor vascular targeting with proprietary compounds which attack the established blood supply that feeds a cancer. Adherex is distinguished from other small and mid-cap biopharmaceutical companies by its substantial intellectual property portfolio, having four products already in clinical development and its rich and exciting preclinical pipeline.

牋牋With a management team that is very strong in oncology and pharmaceutical development, Adherex's mission is to become an industry leader in cancer therapeutics.